The role of CXCR2 in promoting metastasis alongside the evidence of elevated CXCR2 in metastatic disease compared to localized disease may suggest that patients with metastatic disease will benefit from a combination of immunotherapy and CXCR2 antagonism. The gene discussed is CXCR2; the disease is metastatic neoplasm.